Cargando…

The metabolic effects of mirabegron are mediated primarily by β(3)‐adrenoceptors

The β(3)‐adrenoceptor agonist mirabegron is approved for use for overactive bladder and has been purported to be useful in the treatment of obesity‐related metabolic diseases in humans, including those involving disturbances of glucose homeostasis. We investigated the effect of mirabegron on glucose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dehvari, Nodi, Sato, Masaaki, Bokhari, Muhammad Hamza, Kalinovich, Anastasia, Ham, Seungmin, Gao, Jie, Nguyen, Huong T. M., Whiting, Lynda, Mukaida, Saori, Merlin, Jon, Chia, Ling Yeong, Wootten, Denise, Summers, Roger J., Evans, Bronwyn A., Bengtsson, Tore, Hutchinson, Dana S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437350/ https://www.ncbi.nlm.nih.gov/pubmed/32813332 http://dx.doi.org/10.1002/prp2.643

Ejemplares similares

β-Adrenergic Inhibition of Contractility in L6 Skeletal Muscle Cells
por: Öberg, Anette I., et al.
Publicado: (2011)

Treatment with a β-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesity
por: Kalinovich, Anastasia, et al.
Publicado: (2020)

Acute β-adrenoceptor mediated glucose clearance in brown adipose tissue; a distinct pathway independent of functional insulin signaling
por: Olsen, Jessica M., et al.
Publicado: (2019)

Rosiglitazone and a β(3)-Adrenoceptor Agonist Are Both Required for Functional Browning of White Adipocytes in Culture
por: Merlin, Jon, et al.
Publicado: (2018)

Mirabegron attenuates porcine ureteral contractility via α1-adrenoceptor antagonism
por: Lim, Iris, et al.
Publicado: (2022)

Shikonin Increases Glucose Uptake in Skeletal Muscle Cells and Improves Plasma Glucose Levels in Diabetic Goto-Kakizaki Rats
por: Öberg, Anette I., et al.
Publicado: (2011)

β(3)-Adrenergically induced glucose uptake in brown adipose tissue is independent of UCP1 presence or activity: Mediation through the mTOR pathway
por: Olsen, Jessica M., et al.
Publicado: (2017)

Concentration-dependent alpha(1)-Adrenoceptor Antagonism and Inhibition of Neurogenic Smooth Muscle Contraction by Mirabegron in the Human Prostate
por: Huang, Ru, et al.
Publicado: (2021)

β3 adrenoceptor agonist mirabegron protects against right ventricular remodeling and drives Drp1 inhibition
por: Zhao, Lin, et al.
Publicado: (2022)

Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2014)

Mirabegron: a decade of study
por: Welk, Blayne
Publicado: (2020)

Pharmacokinetics of Mirabegron, a β(3)-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies
por: Iitsuka, Hiromi, et al.
Publicado: (2013)

Orthosteric Binding of ρ-Da1a, a Natural Peptide of Snake Venom Interacting Selectively with the α(1A)-Adrenoceptor
por: Maïga, Arhamatoulaye, et al.
Publicado: (2013)

Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice
por: Kim, Seo-Yeon, et al.
Publicado: (2023)

Inaccuracies in the recently published review on mirabegron
por: Siddiqui, Emad
Publicado: (2013)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Serum sickness–like reaction associated with mirabegron
por: Tan, Marcus G., et al.
Publicado: (2019)

Distinct Conformations of Mirabegron Determined by MicroED
por: Lin, Jieye, et al.
Publicado: (2023)

Myosin 1c: A novel regulator of glucose uptake in brown adipocytes
por: Åslund, Alice, et al.
Publicado: (2021)

Tissue functions mediated by β(3)-adrenoceptors—findings and challenges
por: Michel, Martin C., et al.
Publicado: (2010)

Patient utilization survey of mirabegron prescribed for overactive bladder
por: Rahkola-Soisalo, Päivi, et al.
Publicado: (2019)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
por: Sharaf, Ala’a, et al.
Publicado: (2017)

Mirabegron: The most promising adipose tissue beiging agent
por: Bel, Jocelyn S., et al.
Publicado: (2021)

The combined effect of metformin and mirabegron on diet‐induced obesity
por: Zhao, Xin‐Yuan, et al.
Publicado: (2023)

Comment on: Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo
por: Scandura, Carmen, et al.
Publicado: (2020)

Editorial commentary on “Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo”
por: Yamanishi, Tomonori, et al.
Publicado: (2020)

Effects of combined treatment with fesoterodine and mirabegron in a pelvic congestion rat model: Results from in vitro and in vivo functional studies
por: Sugaya, Kimio, et al.
Publicado: (2019)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
por: Gubbiotti, Marilena, et al.
Publicado: (2019)

Respiratory dysfunction following initiation of mirabegron: A case report
por: Malsin, Elizabeth S., et al.
Publicado: (2019)

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
por: Shaw, Christina, et al.
Publicado: (2023)

Mirabegron displays anticancer effects by globally browning adipose tissues
por: Sun, Xiaoting, et al.
Publicado: (2023)

The Role of Adrenoceptors in the Retina
por: Ruan, Yue, et al.
Publicado: (2020)

Parkin-mediated ubiquitination regulates phospholipase C-γ1
por: Dehvari, Nodi, et al.
Publicado: (2009)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
por: Andersson, Karl-Erik
Publicado: (2013)

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
por: Nazir, Jameel, et al.
Publicado: (2017)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
por: Makhani, Asad, et al.
Publicado: (2020)

Symptom improvement with mirabegron treatment is associated with urobiome changes in adult women
por: Halverson, Thomas, et al.
Publicado: (2022)

Selectivity and Maximum Response of Vibegron and Mirabegron for β(3)-Adrenergic Receptors
por: Brucker, Benjamin M., et al.
Publicado: (2022)

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
por: Sartori, Luisa Gracio Ferreira, et al.
Publicado: (2023)

Amazonian Amphibian Diversity Is Primarily Derived from Late Miocene Andean Lineages
por: Santos, Juan C, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_vdopo1mo5o869cjn4pee48eisb